drugset
drugset / Trial / NCT06225336

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)

NCT06225336 ↗

Phase 1 Terminated 2 enrolled Auregen Biotherapeutics, SA
NaSingle-groupOpen-labelTreatment

Summary

AUR-201 is indicated for the treatment of Grade II, III, or IV unilateral microtia in patients 8 to 29 years of age.

Timeline

Start
2022-11-04
Primary completion
2025-09-10
Completion
2025-09-10

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject AUR-201 Cell therapy — Subcutaneous

Indications

microtia